Pakistan and China Sign $850 Million in Pharmaceutical Deals to Reduce Import Dependence
Pakistan and Chinese companies signed agreements worth $850 million at the Pakistan-China Pharmaceutical and Healthcare B2B Investment Conference in Islamabad on July 17-18. The deals include 16 contracts and 80 memoranda of understanding covering vaccine production, active pharmaceutical ingredients (API), medical devices, clinical trials, and generic formulations. Pakistan currently imports all 13 vaccines in its national immunization program and 95% of the API needed for domestic medicine production, making its healthcare system vulnerable to global disruptions. The agreements aim to establish local manufacturing through joint ventures, technology transfer, and plants in CPEC special economic zones. Pakistan has also approved a National Local Vaccine Production Policy to support this shift. The annual vaccine import bill could reach $1.2 billion by 2030, and local production is expected to reduce costs, save foreign exchange, and improve health security for Pakistan's 240 million people.
Editorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page itself is projected from evidence records.
- Current automated evidence projection